jnj-64281802
Vaccineexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 28, 2020 (NCT04480736)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05201794 | Phase 2 | Jan 18, 2023 | — |
| NCT05201937 | Phase 1 | Feb 23, 2022 | — |
| NCT05048875 | Phase 2 | Jan 20, 2022 | Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT04906980 | Phase 2 | Oct 31, 2021 | Janssen Pharmaceutica NV |
| NCT04480736 | Phase 2 | Jul 28, 2020 | Janssen Pharmaceutica NV |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 3 | 2 | 1 | 2020 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1